Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
Phase 1
Recruiting
- Conditions
- BRCA2 MutationBRCA MutationPALB2 Gene MutationCheckpoint Kinase 2 Gene MutationBRCA1 MutationATM Gene Mutation
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Pamela Munster
- Target Recruit Count
- 18
- Registration Number
- NCT06177171
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
Phase 1
Withdrawn
- Conditions
- PIK3CA MutationSolid Tumors, AdultHuman Papillomavirus-Related CarcinomaMetastatic Malignant Solid NeoplasmHPV-Related Squamous Cell CarcinomaPIK3CA Mutation-Related TumorsHuman Papillomavirus-Related Squamous Cell CarcinomaLocally Advanced Malignant Solid Neoplasm
- Interventions
- Drug: Hyperpolarized Carbon-13 (13C) PyruvateDevice: Continuous Glucose Monitor (CGM)
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2022-12-27
- Lead Sponsor
- Pamela Munster
- Registration Number
- NCT05472220
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
Phase 1
Withdrawn
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Hormone Receptor Positive Breast CarcinomaLocally Advanced Breast CarcinomaMetastatic Breast CarcinomaMetastatic Endometrioid AdenocarcinomaMetastatic Primary Peritoneal Carcinoma
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Pamela Munster
- Registration Number
- NCT04498520
Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair
Phase 1
Completed
- Conditions
- Solid Tumor, Unspecified, Adult
- Interventions
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Pamela Munster
- Target Recruit Count
- 22
- Registration Number
- NCT03318445
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets
Early Phase 1
Withdrawn
- Conditions
- Documented Her2 OverexpressionAdvanced Solid TumorBrain MetastasesNeurologically Stable
- Interventions
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- Pamela Munster
- Registration Number
- NCT02735798
Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies
- First Posted Date
- 2015-12-03
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Pamela Munster
- Target Recruit Count
- 28
- Registration Number
- NCT02620839
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer
Phase 1
Terminated
- Conditions
- Triple Negative Metastatic Breast CancerBRCA-mutated Solid Tumor
- Interventions
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Pamela Munster
- Target Recruit Count
- 23
- Registration Number
- NCT02358200
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
Pazopanib in Combination with PCI-24781 in Patients with Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Metastatic Solid Tumors
- Interventions
- Drug: PZP115891, PCI-24781
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Pamela Munster
- Target Recruit Count
- 90
- Registration Number
- NCT01543763
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
© Copyright 2025. All Rights Reserved by MedPath